Therapeutic options for gastrointestinal carcinoids.

Area of Science:

• Oncology
• Gastroenterology

Background:

• Carcinoid tumors are neuroendocrine neoplasms.
• Metastatic disease at diagnosis is common, complicating curative treatment.
• Optimal therapy balances tumor burden reduction, symptom management, and quality of life.

Purpose of the Study:

• To review current therapeutic strategies for carcinoid tumors.
• To highlight the role of somatostatin analogues in managing carcinoid syndrome.
• To assess the efficacy and limitations of various treatment modalities.

Main Methods:

• Literature review of surgical, medical, and radiological treatments.
• Analysis of long-term therapy focusing on symptom alleviation.
• Evaluation of emerging treatments like peptide-receptor-targeted radiotherapy.

Main Results:

• Wide surgical resection is optimal for localized disease; palliative surgery reduces tumor burden.
• Endoscopic excision is suitable for select gastric and rectal carcinoid tumors.
• Long-acting somatostatin analogues are the cornerstone for symptom control and quality of life improvement.
• Chemotherapy and radiotherapy show limited efficacy.
• Hepatic metastases may be treated with surgery, ablation, or embolization.
• Peptide-receptor-targeted radiotherapy shows promise but is investigational.

Conclusions:

• Management of carcinoid tumors requires a multidisciplinary approach.
• Somatostatin analogues are highly effective for symptom management and improving quality of life.
• While various treatments exist, long-term therapy emphasizes palliation and supportive care for advanced disease.